Inavolisib plus hormone therapy for advanced breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a new targeted therapy, inavolisib, combined with standard hormone therapy and a CDK4/6 inhibitor for people with a specific genetic mutation (PIK3CA) in their hormone receptor-positive, HER2-negative advanced breast cancer that has not been treated before. It compares this combination to a placebo plus the same standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced breast cancer that is hormone receptor-positive and HER2-negative.
- Your tumor has a PIK3CA mutation.
- You have not received any prior treatment for advanced or metastatic breast cancer.
- You can provide a tissue sample from your tumor.
- You have measurable disease (tumors that can be tracked with scans).
- You are in good general health (able to carry on daily activities).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two different combinations of medicines for people with a certain type of advanced breast cancer (HR-positive, HER2-negative) that has a specific gene change called PIK3CA. The goal is to see which combination is better at slowing down the cancer.
This trial tests whether a new targeted pill (inavolisib) plus hormone therapy (fulvestrant) can slow or stop breast cancer growth in people whose cancer has a specific genetic change called a PIK3CA mutation. It is for patients whose disease worsened after previous hormone-and-CDK-inhibitor treatment.
This study tests a new drug called inavolisib for people with early-stage breast cancer that has a specific genetic change (PIK3CA mutation). The goal is to see if adding this drug to standard hormone therapy is safe and effective before surgery.
This study observes how inavolisib (a new cancer drug) works in patients with a specific type of advanced breast cancer in everyday clinical practice. Researchers will track your medical records, imaging, and lab results over time to understand how well the treatment works and its safety profile.
This trial tests a combination of three drugs (inavolisib, ribociclib, and fulvestrant) compared to a placebo plus two of the drugs (ribociclib and fulvestrant) for people with advanced hormone receptor-positive breast cancer who have not had prior treatment for advanced disease. The goal is to see if adding inavolisib improves outcomes.
This study tests a combination of three drugs (inavolisib, ribociclib, and fulvestrant) for women with advanced breast cancer that is hormone-receptor positive and HER2-negative, with a specific genetic mutation (PIK3CA). The goal is to see if this combination can shrink or control the cancer better than standard treatments.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.